| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Mehra MR | |
| P2860 | cites work | High diversity of non-human leukocyte antigens in transplant-associated coronary artery disease1 | Q30920620 |
| Long-term outcome of cardiac allograft vasculopathy treated by transmyocardial laser revascularization: early rewards, late losses | Q31805700 | ||
| Impact of intravascular ultrasound in understanding transplant coronary artery disease | Q33587371 | ||
| The role of percutaneous transluminal coronary angioplasty in heart transplant recipients | Q33950478 | ||
| Mycophenolate mofetil and its mechanisms of action | Q33957177 | ||
| Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients | Q33968031 | ||
| Cardiac transplant vasculopathy | Q34104081 | ||
| Effect of mycophenolate mofetil therapy on lymphocyte activation in heart transplant recipients | Q34156177 | ||
| TOR inhibitors and cardiac allograft vasculopathy: is inhibition of intimal thickening an adequate surrogate of benefit? | Q35125737 | ||
| Immunosuppression and transplant vascular disease: benefits and adverse effects | Q35580683 | ||
| De novo production of antibodies after heart or lung transplantation should be regarded as an early warning system | Q35737758 | ||
| Effect of cyclosporine, mycophenolic acid, and rapamycin on the proliferation of rat aortic vascular smooth muscle cells: in vitro study | Q38525562 | ||
| The management of post-cardiac transplantation coronary artery disease | Q39468847 | ||
| Intravascular ultrasound evidence of angiographically silent progression in coronary atherosclerosis predicts long-term morbidity and mortality after cardiac transplantation | Q40426540 | ||
| Surrogate markers for late cardiac allograft survival | Q40503705 | ||
| The clinical significance of antibodies to human vascular endothelial cells after cardiac transplantation | Q41609190 | ||
| Relationship between coronary function by positron emission tomography and temporal changes in morphology by intravascular ultrasound (IVUS) in transplant recipients | Q41665035 | ||
| Longitudinal study of vascular remodeling in coronary arteries after heart transplantation | Q41743374 | ||
| Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial. | Q42631747 | ||
| Tacrolimus or cyclosporine: which is the better partner for mycophenolate mofetil in heart transplant recipients? | Q42636782 | ||
| Donor hepatitis-C seropositivity is an independent risk factor for the development of accelerated coronary vasculopathy and predicts outcome after cardiac transplantation | Q42983901 | ||
| Multicenter intravascular ultrasound validation study among heart transplant recipients: outcomes after five years. | Q43468457 | ||
| Effective treatment of hyperhomocysteinemia in heart transplant recipients with and without renal failure | Q43546995 | ||
| Metabolic abnormalities characteristic of dysmetabolic syndrome predict the development of transplant coronary artery disease: a prospective study | Q43594092 | ||
| Homocysteine--a treatable risk factor for allograft vascular disease after heart transplantation? | Q43670746 | ||
| Mycophenolate mofetil versus azathioprine in patients surviving the initial cardiac transplant hospitalization: an analysis of the Joint UNOS/ISHLT Thoracic Registry | Q43811358 | ||
| The Registry of the International Society for Heart and Lung Transplantation: twenty-first official adult heart transplant report--2004. | Q43820353 | ||
| Mycophenolate mofetil decreases antibody production after cardiac transplantation | Q43880383 | ||
| Usefulness of plasma vitamin B(6), B(12), folate, homocysteine, and creatinine in predicting outcomes in heart transplant recipients | Q43927908 | ||
| Effect of vitamins C and E on progression of transplant-associated arteriosclerosis: a randomised trial | Q43953917 | ||
| Cardiac transplant patients response to the (31)P MRS stress test | Q43976154 | ||
| Cytomegalovirus infection in heart transplant recipients is associated with impaired endothelial function | Q43997244 | ||
| Coronary Doppler measurements do not predict progression of cardiac allograft vasculopathy: analysis by serial intracoronary Doppler, dobutamine stress echocardiography, and intracoronary ultrasound | Q44090354 | ||
| Effect of immunosuppressive regimen on novel markers of atherothrombosis in heart transplantation: homocysteine, c-reactive protein, and mean platelet volume | Q44101680 | ||
| Retransplantation in 7,290 primary transplant patients: a 10-year multi-institutional study | Q44158375 | ||
| Palliation of allograft vasculopathy with transluminal angioplasty: a decade of experience | Q44267537 | ||
| Is all intimal proliferation created equal in cardiac allograft vasculopathy? The quantity-quality paradox | Q44312066 | ||
| Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation1,2 | Q44419285 | ||
| Use of Rapamycin Slows Progression of Cardiac Transplantation Vasculopathy | Q44438446 | ||
| Plasma C-reactive protein as a marker of cardiac allograft vasculopathy in heart transplant recipients | Q44541872 | ||
| Reduced myocardial perfusion reserve and transmural perfusion gradient in heart transplant arteriopathy assessed by magnetic resonance imaging | Q44588104 | ||
| Heart transplantation in patients with diabetes mellitus in the current era. | Q44612735 | ||
| Mycophenolate mofetil significantly reduces leukocyte graft infiltration after heterotopic cardiac transplantation in a rat model: comparative study with cyclosporine and FK 506 | Q44612737 | ||
| Coronary angioplasty, atherectomy and bypass surgery in cardiac transplant recipients | Q44642913 | ||
| Long-term effect of combined vitamins E and C on coronary and peripheral endothelial function | Q44771229 | ||
| Changes in coronary endothelial function predict progression of allograft vasculopathy after heart transplantation | Q44799035 | ||
| Comparison of intravenous ganciclovir and cytomegalovirus hyperimmune globulin pre-emptive treatment in cytomegalovirus-positive heart transplant recipients | Q44829190 | ||
| Comparison of combined prophylaxis of cytomegalovirus hyperimmune globulin plus ganciclovir versus cytomegalovirus hyperimmune globulin alone in high-risk heart transplant recipients. | Q44839199 | ||
| Immune and nonimmune predictors of cardiac allograft vasculopathy onset and severity: multivariate risk factor analysis and role of immunosuppression | Q44899020 | ||
| Metaanalysis of statins and survival in de novo cardiac transplantation | Q44976491 | ||
| Usefulness of an elevated B-type natriuretic peptide to predict allograft failure, cardiac allograft vasculopathy, and survival after heart transplantation | Q45027819 | ||
| Predictive model to assess risk for cardiac allograft vasculopathy: an intravascular ultrasound study | Q45049707 | ||
| Increased plasma homocysteine concentrations accelerate cardiac allograft vasculopathy | Q45147786 | ||
| A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators. | Q46186465 | ||
| Role of vascular remodeling in the pathogenesis of early transplant coronary artery disease: a multicenter prospective intravascular ultrasound study | Q46427496 | ||
| Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients. | Q46492984 | ||
| Early constriction or expansion of the external elastic membrane area determines the late remodeling response and cumulative lumen loss in transplant vasculopathy: an intravascular ultrasound study with 4-year follow-up | Q47919955 | ||
| Prognostic importance of intimal thickness as measured by intracoronary ultrasound after cardiac transplantation. | Q50609706 | ||
| Impact of prophylactic immediate posttransplant ganciclovir on development of transplant atherosclerosis: a post hoc analysis of a randomized, placebo-controlled study. | Q50649143 | ||
| Cardiac allograft rejection late after transplantation is a risk factor for graft coronary artery disease. | Q50902980 | ||
| High homocysteine, low folate, and low vitamin B6 concentrations: prevalent risk factors for vascular disease in heart transplant recipients. | Q51571251 | ||
| The registry of the International Society for Heart and Lung Transplantation: twentieth official adult heart transplant report--2003. | Q53300309 | ||
| Lack of usefulness of electron beam computed tomography for detecting coronary allograft vasculopathy. | Q53618399 | ||
| The impact of mode of donor brain death on cardiac allograft vasculopathy: an intravascular ultrasound study. | Q53643113 | ||
| Humoral immunity to vimentin is associated with cardiac allograft injury in nonhuman primates. | Q53657340 | ||
| Relationship Among Epicardial Coronary Disease, Tissue Myocardial Perfusion, and Survival in Heart Transplantation | Q57652916 | ||
| C-Reactive protein and cardiac allograft vasculopathy | Q57652958 | ||
| Coronary stenting in cardiac allograft vasculopathy | Q57652996 | ||
| An intravascular ultrasound study of the influence of angiotensin-converting enzyme inhibitors and calcium entry blockers on the development of cardiac allograft vasculopathy | Q57653018 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | prevention | Q1717246 |
| P304 | page(s) | 1248-1256 | |
| P577 | publication date | 2006-06-01 | |
| P1433 | published in | American Journal of Transplantation | Q4744273 |
| P1476 | title | Contemporary concepts in prevention and treatment of cardiac allograft vasculopathy | |
| P478 | volume | 6 |
| Q36887068 | A novel pathway of chronic allograft rejection mediated by NK cells and alloantibody |
| Q49996766 | Adherence to Mediterranean and low-fat diets among heart and lung transplant recipients: a randomized feasibility study |
| Q46295855 | Advancing immunosuppression in heart transplantation: "one step forward, two steps back |
| Q35091339 | Anticardiac myosin immunity and chronic allograft vasculopathy in heart transplant recipients |
| Q34136559 | Assessment of sub-clinical acute cellular rejection after heart transplantation: comparison of cardiac magnetic resonance imaging and endomyocardial biopsy |
| Q37994305 | Biomarkers of heart transplant rejection: the good, the bad, and the ugly! |
| Q36993722 | Cardiac allograft vasculopathy and insulin resistance--hope for new therapeutic targets |
| Q36728769 | Cardiac retransplantation is an efficacious therapy for primary cardiac allograft failure. |
| Q33811918 | Connective tissue growth factor promotes fibrosis downstream of TGFbeta and IL-6 in chronic cardiac allograft rejection. |
| Q38592122 | Current diagnostic and treatment strategies for cardiac allograft vasculopathy. |
| Q45356815 | Cytomegalovirus infection does not accelerate microvasculopathy development in heart transplant recipients |
| Q84784692 | Different role of advanced glycation end products in pathology of transplanted heart in patients with or without diabetes mellitus type 2 |
| Q34662795 | Early inflammatory markers are independent predictors of cardiac allograft vasculopathy in heart-transplant recipients |
| Q38061056 | Effect of maintenance immunosuppressive drugs on virus pathobiology: evidence and potential mechanisms |
| Q44924891 | Elevated serum uric acid levels following heart transplantation predict all-cause and cardiac mortality |
| Q38260052 | Extracorporeal photopheresis after heart transplantation |
| Q85089706 | In the era of the universal use of statins dyslipidemia's are still common in heart transplant recipients: a cross-sectional study |
| Q85351968 | Incidence and treatment of lymphedema in heart transplant patients treated with everolimus |
| Q84409881 | Increased incidence of acute graft rejection on calcineurin inhibitor-free immunosuppression after heart transplantation |
| Q36976632 | Induction of vascular atrophy as a novel approach to treating restenosis. A review |
| Q38218005 | Interacting mechanisms in the pathogenesis of cardiac allograft vasculopathy |
| Q37941478 | Mechanism of arterial remodeling in chronic allograft vasculopathy |
| Q33800446 | Medium-term outcome of recipients of marginal donor hearts selected with new stress-echocardiographic techniques over standard criteria |
| Q42461920 | Microvasculopathy observed in early or late endomyocardial biopsies is not related to angiographically confirmed transplanted heart coronary vasculopathy |
| Q38614686 | Novel therapeutic and diagnostic management of heart transplant patients |
| Q45222416 | Off-pump coronary artery bypass grafting for a left main lesion due to cardiac allograft vasculopathy in Japan: first report of a case |
| Q43426990 | Outcome after heart transplantation from older donor age: expanding the donor pool |
| Q52680428 | Outcomes and survival following heart retransplantation for cardiac allograft failure: a systematic review and meta-analysis. |
| Q85089696 | Paradox of advanced glycation end-products in late cardiac biopsies of heart transplant recipients |
| Q37709678 | Recipient-derived EDA fibronectin promotes cardiac allograft fibrosis |
| Q38004403 | Role of regulatory T cells in the promotion of transplant tolerance |
| Q52863308 | SDF-1/CXCR4/CXCR7 is pivotal for vascular smooth muscle cell proliferation and chronic allograft vasculopathy. |
| Q37773292 | TGF-beta, IL-6, IL-17 and CTGF direct multiple pathologies of chronic cardiac allograft rejection |
| Q41847223 | The CECARI Study: Everolimus (Certican®) Initiation and Calcineurin Inhibitor Withdrawal in Maintenance Heart Transplant Recipients with Renal Insufficiency: A Multicenter, Randomized Trial |
| Q57652824 | The Cardiac Allograft Is Going Up in Smoke: A Call to Action |
| Q45399182 | The effect of Epstein-Barr virus infection on medium-term survival after orthotopic heart transplantation |
| Q79899533 | The influence of cytomegalovirus infection, confirmed by pp65 antigen presence, on the development of cardiac allograft vasculopathy |
| Q38002150 | The presentation and diagnosis of coronary allograft vasculopathy in pediatric heart transplant recipients. |
| Q37587334 | Tim-1-Fc suppresses chronic cardiac allograft rejection and vasculopathy by reducing IL-17 production |
| Q34257142 | Value of the first post-transplant biopsy for predicting long-term cardiac allograft vasculopathy (CAV) and graft failure in heart transplant patients |
Search more.